GLP-1 coverage in Michigan (2026)

Medicaid rules, licensing, compounding, and cash prices, each with its source

Reviewed by the WeighedHealth Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.

Content current as of September 2026; updated when guidance or availability changes.

Last verified September 15, 2026by WeighedHealth Editorial Team against primary sources

Michigan Medicaid

Since January 1, 2026, Michigan Medicaid covers GLP-1s for obesity only for morbid obesity, after documented failure of other weight-loss interventions including PDL-preferred anti-obesity drugs, and only to avoid bariatric surgery. Prior authorizations approved before the change stay valid until their 6-month term ends.

Source: MDHHS bulletin L 25-73
Source: University of Michigan: Medicaid's new GLP-1 limits explained

Commercial plans set their own rules. See the criteria each carrier publishes on our insurance coverage pages.

Telehealth licensing in Michigan

Michigan's IMLC membership lapsed on March 28, 2025 and was restored by Public Act 6 of 2026 (HB 5455), signed March 26, 2026.

Source: Michigan Legislature: HB 5455

The compact speeds up licensing for physicians who practice in several states. A telehealth clinician still needs a license in the state where you are when you are treated.

Compounded GLP-1s

On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.

Source: FDA press announcement (April 30, 2026)
Source: Federal Register 91 FR 23431 (May 1, 2026)
Source: Federal Register: comment period extended (June 26, 2026)

Background: our guide to compounding rules.

Cash prices without insurance

NovoCare Pharmacy sells Wegovy pens to cash-pay patients for $349 a month ($199 a month for the first two months for new patients through December 31, 2026). LillyDirect sells Zepbound vials for $299 (2.5 mg), $399 (5 mg), and $449 (7.5 to 15 mg) a month when refilled on time.

Source: NovoCare Pharmacy: Wegovy offer
Source: LillyDirect: Zepbound

Adult obesity rate: CDC Adult Obesity Prevalence Maps (BRFSS 2024).

GLP-1 in Michigan: common questions

Does Michigan Medicaid cover Wegovy or Zepbound for weight loss?+

Limited coverage. Since January 1, 2026, Michigan Medicaid covers GLP-1s for obesity only for morbid obesity, after documented failure of other weight-loss interventions including PDL-preferred anti-obesity drugs, and only to avoid bariatric surgery. Prior authorizations approved before the change stay valid until their 6-month term ends.

Is compounded semaglutide still legal in Michigan?+

Compounding rules for semaglutide and tirzepatide are set federally, not by Michigan. On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.

What does Wegovy or Zepbound cost without insurance in Michigan?+

Manufacturer cash prices are the same in every state. NovoCare Pharmacy sells Wegovy pens to cash-pay patients for $349 a month ($199 a month for the first two months for new patients through December 31, 2026). LillyDirect sells Zepbound vials for $299 (2.5 mg), $399 (5 mg), and $449 (7.5 to 15 mg) a month when refilled on time.